The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...

The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

On January 7, 2026, the First Circuit Court of Appeals denied the federal government’s emergency motion to stay a district ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

HHS may reconsider blocked 340B rebate pilot after courts halt the program, signaling potential changes for drug discount policies in 2024.

Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal ...

The Trump administration has signaled plans to drop its appeal of a court order that blocked a pilot from changing payment terms for the 340B drug discount program.

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and financial resilience in 2026.

A federal judge granted a temporary restraining order to block a pilot program aimed at keeping better tabs on the federal340B program.

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...

Founded on pioneering research and industry leadership, ARxIUM® is committed to overcoming the most complex challenges ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...